63. Idiopathic thrombocytopenic purpura Clinical trials / Disease details


Clinical trials : 391 Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004103-12-BG
(EUCTR)
15/12/202022/06/2020A Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune ThrombocytopeniaA Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia Primary immune thrombocytopenia
MedDRA version: 23.0;Level: LLT;Classification code 10050245;Term: Autoimmune thrombocytopenia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: TAK-079
Product Code: TAK-079
INN or Proposed INN: Mezagitamab
Other descriptive name: TAK-079
Takeda Development Center Americas, Inc. (Takeda)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
54Phase 2United States;Slovenia;Greece;Spain;Ukraine;Croatia;Bulgaria;Germany;Italy;Japan;China